Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
19 hedge funds and large institutions have $394K invested in Statera Biopharma, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
2% less capital invested
Capital invested by funds: $404K → $394K (-$10K)
14% less funds holding
Funds holding: 22 → 19 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.3K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
+$1.82K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$150 |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$9 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$38K |
| 2 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$5.17K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.24K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$89 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $248K | – | – | – |
|
|
LTFS
2
Ladenburg Thalmann Financial Services
Miami,
Florida
| $82K | -$5.17K | -2,200 | -6% |
|
3
Geode Capital Management
Boston,
Massachusetts
| $47K | – | – | – |
|
|
BA
4
BlackRock Advisors
Wilmington,
Delaware
| $8K | – | – | – |
|
|
5
Morgan Stanley
New York
| $4K | +$2.3K | +981 | +358% |
|
|
BFA
6
BlackRock Fund Advisors
San Francisco,
California
| $2K | +$150 | +64 | +10% |
|
|
IA
7
IFP Advisors
Tampa,
Florida
| $2K | +$1.82K | +775 | New |
|
|
WA
8
Winfield Associates
Cleveland,
Ohio
| $1K | – | – | – |
|
|
VKH
9
Virtu KCG Holdings
New York
| – | -$38K | -14,973 | Closed |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$3.24K | -1,379 | -93% |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| – | -$3K | -1,114 | Closed |
|
|
12
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$89 | -38 | -55% |
|
|
13
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$9 | +4 | +5% |
|
|
AG
14
Advisor Group
Phoenix,
Arizona
| – | +$87 | +37 | New |
|
STAB Hedge Fund Activity: Q2 2016 in Review
19 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q2 2016, worth a combined $394K — down 2.5% from $404K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of STAB and 2 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Morgan Stanley, adding an estimated $2.3K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $38K sold.
- 19 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q2 2016, down from 22 in Q1 2016.
- Funds reported $394K of Statera Biopharma, Inc. Common Stock stock for Q2 2016, down 2.5% quarter-over-quarter.
- 2 funds opened new Statera Biopharma, Inc. Common Stock positions in Q2 2016 and 5 closed out, a net change of -3 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q2 2016 was Morgan Stanley, an estimated $2.3K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q2 2016 was Virtu KCG Holdings, an estimated $38K sold.
Based on aggregated 13F filings for Q2 2016.